货号:A101377
同义名:
顺式-乙醇酸二氨合铂(II)
/ NSC 375101D; NSC 375101
Nedaplatin 是一种顺铂衍生物,对肿瘤克隆形成单位的 IC50 为 94 μM。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 靶点 |
|
| 描述 | Nedaplatin is a derivative of cisplatin which produced less nausea & vomiting and nephrotoxicity. In the phase I study, the MTD was 120 mg/m2 and the DLF was a bone marrow suppression[3]. he topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter concentrations[4]. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinum complex. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At the high-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-term tumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (NSC 375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, the sequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU was demonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinical therapy[5]. Autophagy played a cytoprotective role in nedaplatin-induced cytotoxicity of HNE1/DDP and CNE2/DDP cells[6]. |
| Concentration | Treated Time | Description | References | |
| HEK293 | 0.5, 1, 2, 4, 8, 10, 20 μg/mL | 72 hours | Evaluate the cytotoxicity of free and liposomal Nedaplatin on HEK293 cells. Results showed no significant increase in cytotoxicity with liposomal Nedaplatin. | Pharmaceutics. 2020 Sep 10;12(9):863. |
| WI-38 | 0.5, 1, 2, 4, 8, 10, 20 μg/mL | 72 hours | Evaluate the cytotoxicity of free and liposomal Nedaplatin on WI-38 cells. Results showed no significant increase in cytotoxicity with liposomal Nedaplatin. | Pharmaceutics. 2020 Sep 10;12(9):863. |
| U2OS | 0.5, 1, 2, 4, 8, 10, 20 μg/mL | 72 hours | Evaluate the cytotoxicity of free and liposomal Nedaplatin on U2OS cells. Results showed that liposomal Nedaplatin significantly reduced cell viability at lower concentrations. | Pharmaceutics. 2020 Sep 10;12(9):863. |
| A549 | 0.5, 1, 2, 4, 8, 10, 20 μg/mL | 72 hours | Evaluate the cytotoxicity of free and liposomal Nedaplatin on A549 cells. Results showed that liposomal Nedaplatin significantly increased cytotoxicity at all tested concentrations. | Pharmaceutics. 2020 Sep 10;12(9):863. |
| MDA-MB-468 | 0.067 µM | 24 hours | Evaluate the cytotoxicity of nedaplatin on TNBC cells, results showed cytotoxicity to MDA-MB-468 cells at the highest tested dose | Cell Death Discov. 2024 Jan 29;10(1):57. |
| BT-549 | 0.15 µM | 24 hours | Evaluate the cytotoxicity of nedaplatin on TNBC cells, results showed high cytotoxicity to CAL-148 cells at the highest tested dose | Cell Death Discov. 2024 Jan 29;10(1):57. |
| Administration | Dosage | Frequency | Description | References | ||
| Zebrafish | HCC1806 and MCF-7 cell xenograft models | 25 µM | 48 hours | Evaluate the effect of nedaplatin combined with bortezomib on tumor regression, results showed reduced tumor volume | Cell Death Discov. 2024 Jan 29;10(1):57. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03328234 | IMRT With or Without Concurren... 展开 >>t Chemotherapy for Esophageal Cancer 收起 << | Phase 3 | Recruiting | December 31, 2022 | China ... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, China, 100021 Contact: Xin Wang, MD +861013311583220 beryl_wx2000@163.com 收起 << |
| NCT03731442 | Esophageal Cancer | Phase 3 | Recruiting | October 31, 2027 | China, Beijing ... 展开 >> Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Zefen Xiao, MD 收起 << |
| NCT03308552 | Esophageal Neoplasms | Phase 3 | Recruiting | August 30, 2021 | China, Beijing ... 展开 >> Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Recruiting Beijing, Beijing, China, 100021 Contact: Zefen Xiao, MD 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.30mL 0.66mL 0.33mL |
16.49mL 3.30mL 1.65mL |
32.98mL 6.60mL 3.30mL |
|
| CAS号 | 95734-82-0 |
| 分子式 | C2H8N2O3Pt |
| 分子量 | 303.17 |
| SMILES Code | O=C1[O-][Pt+2]([NH3])([NH3])[O-]C1 |
| MDL No. | MFCD00866374 |
| 别名 | 顺式-乙醇酸二氨合铂(II) ;NSC 375101D; NSC 375101 |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
| 溶解方案 |
H2O: 8 mg/mL(26.39 mM),配合低频超声,并水浴加热至45℃助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1